Transplantation Research Center, Children's Hospital Boston and Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Anticancer Agents Med Chem. 2010 Feb;10(2):131-6. doi: 10.2174/187152010790909254.
Cancer stem cells (CSCs), also known as tumor-initiating cells, have been identified in several human malignancies, including human malignant melanoma. The frequency of malignant melanoma-initiating cells (MMICs), which are identified by their expression of ATP-binding cassette (ABC) family member ABCB5, correlates with disease progression in human patients. Furthermore, targeted MMIC ablation through ABCB5 inhibits tumor initiation and growth in preclinical xenotransplantation models, pointing to potential therapeutic promise of the CSC concept. Recent advances also show that CSCs can exert pro-angiogenic roles in tumor growth and serve immunomodulatory functions related to the evasion of host anti-tumor immunity. Thus, MMICs might initiate and sustain tumorigenic growth not only as a result of CSC-intrinsic self-renewal, differentiation and proliferative capacity, but also based on pro-tumorigenic interactions with the host environment.
癌症干细胞(CSCs),也称为肿瘤起始细胞,已在几种人类恶性肿瘤中被鉴定出来,包括人类恶性黑色素瘤。通过表达三磷酸腺苷结合盒(ABC)家族成员 ABCB5 鉴定出的恶性黑色素瘤起始细胞(MMICs)与人类患者的疾病进展相关。此外,通过 ABCB5 靶向 MMIC 消融可抑制临床前异种移植模型中的肿瘤起始和生长,这表明 CSC 概念具有潜在的治疗前景。最近的进展还表明,CSC 可在肿瘤生长中发挥促血管生成作用,并发挥与宿主抗肿瘤免疫逃避相关的免疫调节功能。因此,MMIC 不仅可能由于 CSC 内在的自我更新、分化和增殖能力而引发和维持致瘤性生长,而且还可能基于与宿主环境的促肿瘤发生相互作用。